Gilbert Greub is an expert in Infectiology at University Hospital of Lausanne (Switzerland). Gilbert Greub has authored 661 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 1 of them ongoing. SLR score: 2,161 (community average: 125). How the SLR is computed.

LeadR Profile

Gilbert Greub University Hospital of Lausanne Switzerland
2 161 ScienceLeadR Reputation 2161
Network Map

Infectiology

Subspecialties: Public Health - Genetics - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Prof Gilbert Greub is the current director of the Institute of Microbiology of the University Hospital of Lausanne (Switzerland). He is also Chef de Service and head of medical microbiology at the University Hospital of Lausanne. His activities mainly include research, teaching, & diagnostics as a microbiologist, as well as patient care as an infectious diseases specialist.


Born in 1967, he studied medicine at the University of Geneva. Then he did a MD degree at the University of Lausanne and a Phd at the University of Aix-Marseille (France). He specialized as FMH in internal medicine, FMH in infectious diseases, and FAMH in microbiology. Since 2004, he is leading the Center for Research on Intracellular Bacteria, a research center mainly dedicated to the study of chlamydia and chlamydia-related bacteria. Among others, his group recently succesfully studied the division of these bacteria (Jacquier et al Nature Comm 2014; Frandi et al Nature Comm 2014; Jacquier et al Biol Chem 2015), identifying possible new future drug targets, as well as chlamydial toxins (Ardissone & Greub, Appl Environ Microbiol 2024). For all this research on chlamydiae, G Greub received several prices including the European ESCMID young investigator award (2006), the Viollier award (2010), the Leenaards award (2011), the Naef Price (2010), and the Fond Carlo - Philanthropia price from the Lombard-Odier foundation (2016). He is also past president of SSM 2016-2018, the current chair person of the ESCMID study group on mycoplasma and chlamydia (ESGMAC) and the chairman of the International sucommittee for chlamydial taxonomy. Since January 2022, he is leading the national center for tick-borne infections, being active both on bacteria from ticks such as Rhabdochlamydia, Rickettsia, Anaplasma, Borrelia and virus from ticks such as tick-borne encephalitis virus and alongshanvirus. Recently he funded JeuPRO, a company that is distributing the games Krobs & MyKrobs, two games that he created and edited with C. Kebbi from the Institute of Microbiology. In 2026, he also published a comic book on resistant microbes and co-authored an article in Science of the paleomicrobiology of Treponema.

Organizations

Career arc: 1996 - 2026

Source: PubMed

University Hospital of Lausanne

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 661

Citations

Citations: 25 949 1st author: 51 Last author: 269 Unique author: 19


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Fever of unknown origin and splenomegaly in an immunosuppressed Swiss patient: case report of a Neoehrlichia mikurensis infection in a changing climate and review of the literature.
PMID 42746457 — splenomegaly, fever of unknown origin, pancytopenia, climate, zoonoses, therapeutics, infections
Access Microbiol20260
A 16-Year-Old Boy With ARDS and Septic Shock, an Atypical Presentation of Murine Typhus: Case Report and Review of the Literature.
PMID 42725118 — shock, septic, diagnosis, therapeutics, typhus, endemic flea-borne, child
Case Rep Crit Care20260
Conference report: the third Bacterial Genome Sequencing Pan-European Network conference.
PMID 42714841 — genome, bacterial, genome, public health, microbiology, public health surveillance
FEMS Microbiol Lett20260
Moraxella species isolated from blood cultures in Europe (MORAXEu): a multicentre study of epidemiology and antimicrobial susceptibility with complementary phylogenomic analysis of publicly available genomes.
PMID 42698036 — moraxella, epidemiology, blood, genome, microbiology, phylogeny, blood culture, communicable diseases, infections
Eur J Clin Microbiol Infect Dis20260
Nonfermenting Gram-Negative Bacilli Other Than Pseudomonas and Acinetobacter Species in Pediatric Blood Cultures: A Multicenter European Analysis.
PMID 42547924 — blood, piperacillin, tazobactam drug combination, trimethoprim, sulfamethoxazole, pseudomonas, piperacillin, tazobactam, blood culture, communicable diseases, carbapenems, infections, child, acinetobacter
Pediatr Infect Dis J20260

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

N/A 6

By status:

Recruiting 3
Completed 2
Terminated 1

By type:

Observational 4
Interventional 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 1
multicentricup10 1

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram negative Bacteria Causing Bacteremia
NCT05613322 — bacteremia, gram-negative bacteria, multiple chronic conditions, sepsis, bacteria, disease susceptibility
N/ARecruiting2023

LeadR Networks

Main global connection map